Browsing by Author "Junaković, Anamari (55252791400)"
Now showing 1 - 6 of 6
- Results Per Page
- Sort Options
- Some of the metrics are blocked by yourconsent settings
Publication Autonomic dysfunction in people with neuromyelitis optica spectrum disorders(2020) ;Crnošija, Luka (55943212800) ;Krbot Skorić, Magdalena (55915654300) ;Andabaka, Marko (57207949404) ;Junaković, Anamari (55252791400) ;Martinović, Vanja (56925159700) ;Ivanović, Jovana (57196371316) ;Mesaroš, Šarlota (7004307592) ;Pekmezović, Tatjana (7003989932) ;Drulović, Jelena (55886929900)Habek, Mario (14050219000)Aims: To determine the difference in autonomic symptom burden measured with the Composite Autonomic System Score-31 (COMPASS-31) and presence of objective dysautonomia in people with neuromyelitis optica spectrum disorders (pwNMOSD) compared to people with multiple sclerosis (pwMS). Design/Methods: Twenty pwNMOSD and 20 pwMS, matched for age, sex, and disease duration, were enrolled. All patients completed the COMPASS-31. The quantification of cardiovascular autonomic dysfunction (CAD) was made using the two indices of the Composite Autonomic Scoring Scale (CASS): adrenergic index (AI) and cardiovagal index (CI). Results: In all pwNMOSD, COMPASS-31 was >0. Sympathetic dysfunction was present in 8 (40%), parasympathetic dysfunction in 10 (50%), and orthostatic hypotension in 6 (30%) pwNMOSD. This group of patients had higher frequency and level on the pupillomotor domain of the COMPASS-31 compared to pwMS (p = 0.048 and p = 0.006, respectively). A binary logistic regression model showed that drop in diastolic blood pressure (dBP) during tilt-table test and normal function of autonomic nervous system, defined as AI = 0 and CI = 0, were independent predictors of pwNMOSD (p = 0.042 and p = 0.029, respectively). If CAD was present, it was significantly worse in pwNMOSD compared to pwMS (p = 0.003). Conclusion: Significant proportion of pwNMOSD experience dysautonomia, which seems to be different from dysautonomia observed in pwMS. © The Author(s), 2019. - Some of the metrics are blocked by yourconsent settings
Publication Autonomic dysfunction in people with neuromyelitis optica spectrum disorders(2020) ;Crnošija, Luka (55943212800) ;Krbot Skorić, Magdalena (55915654300) ;Andabaka, Marko (57207949404) ;Junaković, Anamari (55252791400) ;Martinović, Vanja (56925159700) ;Ivanović, Jovana (57196371316) ;Mesaroš, Šarlota (7004307592) ;Pekmezović, Tatjana (7003989932) ;Drulović, Jelena (55886929900)Habek, Mario (14050219000)Aims: To determine the difference in autonomic symptom burden measured with the Composite Autonomic System Score-31 (COMPASS-31) and presence of objective dysautonomia in people with neuromyelitis optica spectrum disorders (pwNMOSD) compared to people with multiple sclerosis (pwMS). Design/Methods: Twenty pwNMOSD and 20 pwMS, matched for age, sex, and disease duration, were enrolled. All patients completed the COMPASS-31. The quantification of cardiovascular autonomic dysfunction (CAD) was made using the two indices of the Composite Autonomic Scoring Scale (CASS): adrenergic index (AI) and cardiovagal index (CI). Results: In all pwNMOSD, COMPASS-31 was >0. Sympathetic dysfunction was present in 8 (40%), parasympathetic dysfunction in 10 (50%), and orthostatic hypotension in 6 (30%) pwNMOSD. This group of patients had higher frequency and level on the pupillomotor domain of the COMPASS-31 compared to pwMS (p = 0.048 and p = 0.006, respectively). A binary logistic regression model showed that drop in diastolic blood pressure (dBP) during tilt-table test and normal function of autonomic nervous system, defined as AI = 0 and CI = 0, were independent predictors of pwNMOSD (p = 0.042 and p = 0.029, respectively). If CAD was present, it was significantly worse in pwNMOSD compared to pwMS (p = 0.003). Conclusion: Significant proportion of pwNMOSD experience dysautonomia, which seems to be different from dysautonomia observed in pwMS. © The Author(s), 2019. - Some of the metrics are blocked by yourconsent settings
Publication Sudomotor dysfunction in people with neuromyelitis optica spectrum disorders(2022) ;Habek, Mario (14050219000) ;Andabaka, Marko (57207949404) ;Fanciulli, Alessandra (37072222700) ;Brecl Jakob, Gregor (56545621600) ;Drulović, Jelena (55886929900) ;Leys, Fabian (57216857911) ;Di Pauli, Franziska (25947452900) ;Hegen, Harald (57202373490) ;Auer, Michael (56566208600) ;Pekmezović, Tatjana (7003989932) ;Mesaroš, Šarlota (7004307592) ;Jovičević, Vanja (57306237100) ;Junaković, Anamari (55252791400) ;Wenning, Gregor K. (21647300300) ;Deisenhammer, Florian (7004758773) ;Gabelić, Tereza (15131714000) ;Barun, Barbara (24780632600) ;Adamec, Ivan (41261161500)Krbot Skorić, Magdalena (55915654300)Background and purpose: The aim was to determine the extent of sudomotor dysfunction in people with neuromyelitis optica spectrum disorder (pwNMOSD) and to compare findings with a historical cohort of people with relapsing–remitting multiple sclerosis (pwRRMS). Methods: Forty-eight pwNMOSD were enrolled from four clinical centers. All participants completed the Composite Autonomic Symptom Score 31 to screen for symptoms of sudomotor dysfunction. Sudomotor function was assessed using the quantitative sudomotor axon reflex test. The results were compared with a historical cohort of 35 pwRRMS matched for age, sex and disease duration. Results: Symptoms of sudomotor dysfunction, defined by a score in the Composite Autonomic Symptom Score 31 secretomotor domain >0, were present in 26 (54%) of pwNMOSD. The quantitative sudomotor axon reflex test confirmed a sudomotor dysfunction in 25 (52.1%) of pwNMOSD; in 14 of them (29.2%) sudomotor dysfunction was moderate or severe. No difference was observed between pwNMOSD and pwRRMS in any of the studied parameters. However, symptomatic sudomotor dysfunction was more frequent in pwNMOSD (n = 8, 22.9%) compared to pwRRMS (n = 1, 3%; p = 0.028). In a multivariable logistic regression analysis, statistically significant predictors for symptomatic sudomotor failure were age and diagnosis of neuromyelitis optica spectrum disorder. Conclusions: Sudomotor dysfunction is common in pwNMOSD and more often symptomatic compared to pwRRMS. © 2022 European Academy of Neurology. - Some of the metrics are blocked by yourconsent settings
Publication Sudomotor dysfunction in people with neuromyelitis optica spectrum disorders(2022) ;Habek, Mario (14050219000) ;Andabaka, Marko (57207949404) ;Fanciulli, Alessandra (37072222700) ;Brecl Jakob, Gregor (56545621600) ;Drulović, Jelena (55886929900) ;Leys, Fabian (57216857911) ;Di Pauli, Franziska (25947452900) ;Hegen, Harald (57202373490) ;Auer, Michael (56566208600) ;Pekmezović, Tatjana (7003989932) ;Mesaroš, Šarlota (7004307592) ;Jovičević, Vanja (57306237100) ;Junaković, Anamari (55252791400) ;Wenning, Gregor K. (21647300300) ;Deisenhammer, Florian (7004758773) ;Gabelić, Tereza (15131714000) ;Barun, Barbara (24780632600) ;Adamec, Ivan (41261161500)Krbot Skorić, Magdalena (55915654300)Background and purpose: The aim was to determine the extent of sudomotor dysfunction in people with neuromyelitis optica spectrum disorder (pwNMOSD) and to compare findings with a historical cohort of people with relapsing–remitting multiple sclerosis (pwRRMS). Methods: Forty-eight pwNMOSD were enrolled from four clinical centers. All participants completed the Composite Autonomic Symptom Score 31 to screen for symptoms of sudomotor dysfunction. Sudomotor function was assessed using the quantitative sudomotor axon reflex test. The results were compared with a historical cohort of 35 pwRRMS matched for age, sex and disease duration. Results: Symptoms of sudomotor dysfunction, defined by a score in the Composite Autonomic Symptom Score 31 secretomotor domain >0, were present in 26 (54%) of pwNMOSD. The quantitative sudomotor axon reflex test confirmed a sudomotor dysfunction in 25 (52.1%) of pwNMOSD; in 14 of them (29.2%) sudomotor dysfunction was moderate or severe. No difference was observed between pwNMOSD and pwRRMS in any of the studied parameters. However, symptomatic sudomotor dysfunction was more frequent in pwNMOSD (n = 8, 22.9%) compared to pwRRMS (n = 1, 3%; p = 0.028). In a multivariable logistic regression analysis, statistically significant predictors for symptomatic sudomotor failure were age and diagnosis of neuromyelitis optica spectrum disorder. Conclusions: Sudomotor dysfunction is common in pwNMOSD and more often symptomatic compared to pwRRMS. © 2022 European Academy of Neurology. - Some of the metrics are blocked by yourconsent settings
Publication The incidence of postural orthostatic tachycardia syndrome in the population of Zagreb, Croatia(2020) ;Adamec, Ivan (41261161500) ;Crnošija, Luka (55943212800) ;Ruška, Berislav (57193422440) ;Pavičić, Tin (57193417509) ;Junaković, Anamari (55252791400) ;Skorić, Magdalena Krbot (57200385145) ;Pekmezović, Tatjana (7003989932)Habek, Mario (14050219000)Aim To estimate the incidence of postural orthostatic tachycardia syndrome (POTS) in the population of Zagreb, Croatia, and to determine the patients’ demographic and clinical characteristics. Methods From 2012-2017, we identified patients with POTS by a retrospective analysis of medical records at University Hospital Center Zagreb. Crude incidence rates were directly standardized by age according to the European and World Standard Population. Results Out of 385 patients with suspected POTS, 23 had a definitive POTS diagnosis. The annual incidence ranged from 3.3 to 14.8 per 1 000 000 for both sexes combined. The highest incidence rates were in the age groups 18-29 and 30-39 years, with female predominance. The mean age at diagnosis was 30.7 years (standard deviation ±9.2, range 18-52). The median duration of symptoms at diagnosis was 7.5 months (range 3-180 months). Regarding associated comorbidities, two patients had chronic gastritis and one patient had each of the following: epilepsy, prior subarachnoid hemorrhage, anxiety, mitral insufficiency, obstructive sleep apnea, hypothyreosis, and irritable bowel syndrome. In patients not fulfilling the criteria for POTS, the most common alternative diagnoses were autonomic dysfunction due to multiple sclerosis in 22, anxiety disorder in 17, epilepsy in 16, and orthostatic tachycardia due to deconditioning in 13 patients. Conclusion The data obtained in this study can be used to optimize disease surveillance in population, comprehensive assessment of disease burden, and organization of health care services. © 2020 Medicinska Naklada Zagreb. All rights reserved. - Some of the metrics are blocked by yourconsent settings
Publication Validation and cross-cultural adaptation of the COMPASS-31 in Croatian and Serbian patients with multiple sclerosis(2017) ;Drulović, Jelena (55886929900) ;Gavrilović, Andela (57196371319) ;Crnošija, Luka (55943212800) ;Kisić-Tepavcěvić, Darija (57218390033) ;Skorić, Magdalena Krbot (55915654300) ;Ivanović, Jovana (57196371316) ;Adamec, Ivan (41261161500) ;Dujmović, Irena (6701590899) ;Junaković, Anamari (55252791400) ;Marić, Gorica (56433592800) ;Martinović, Vanja (56925159700) ;Pekmezović, Tatjana (7003989932)Habek, Mario (14050219000)Aim To validate and cross-culturally adapt Croatian and Serbian versions of composite autonomic symptom score- 31 (COMPASS-31) for the detection of dysautonomia in patients with multiple sclerosis (MS). Methods A total of 179 patients, 67 with clinically isolated syndrome (CIS) and 112 with MS, completed the COMPASS- 31 at two MS centers in Zagreb and Belgrade between April 1 and October 31, 2016. Demographic and clinical data including age, gender, MS phenotypes, and the Expanded Disability Status Scale (EDSS) score were collected. Results The Cronbach's alpha coefficient of COMPASS-31 total score was 0.844 for the Croatian MS sample and 0.779 for the Serbian MS sample. A joint analysis yielded Cronbach's alpha coefficients ranging from 0.394 to 0.796, with values in four domains higher than 0.700. In Croatian and Serbian samples and the total study sample, the Cronbach's alpha coefficient of COMPASS-31 was 0.785. Reproducibility measured by intra-class correlation coefficient (ICC) was acceptable (ICC = 0.795). With regard to the clinical validity, significant correlation was found between EDSS and the COMPASS-31 total score (P < 0.001). Furthermore, significant differences between MS phenotypes were detected for bladder and gastrointestinal domains and for the COMPASS-31 total score (P < 0.001, P = 0.005, and P = 0.027, respectively). Finally, significant differences between MS phenotypes in patients with score > 0, which implies the existence of at least one of the symptoms investigated in each domain, were detected for secretomotor and bladder domains (P = 0.015 and P < 0.001, respectively). Conclusion COMPASS-31 represents a valid and acceptable self-assessment instrument for the detection of dysautonomia in MS patients.
